Big pharma has taken a less heavy handed approach to relationships as cutbacks have made outsourcing key, according to Stephen Munk, CEO of Ash Stevens.
In the past Ash Stevens was competing with in-house big pharma capacity, said Munk, but the need to trim operations has shifted the environment. This has been accompanied by a change in attitude, with big pharma becoming less heavy handed and more open to strong relationships.
Typically Ash Stevens will establish a prime contact who acts as “a weaver of the entire fabric of the process”. This ensures one point of contact understands all elements of the project, from engineering requirements to regulatory affairs.